248 related articles for article (PubMed ID: 38202856)
21. Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Int J Oncol; 2018 Jun; 52(6):2143-2154. PubMed ID: 29620166
[TBL] [Abstract][Full Text] [Related]
22. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.
Xiaomeng F; Lei L; Jinghong A; Juan J; Qi Y; Dandan Y
Braz J Med Biol Res; 2020; 53(6):e8885. PubMed ID: 32401925
[TBL] [Abstract][Full Text] [Related]
23. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
24. Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells.
Xu L; Xu Y; Zheng J; Zhao Y; Wang H; Qi Y
Oncol Lett; 2021 Jul; 22(1):569. PubMed ID: 34113397
[TBL] [Abstract][Full Text] [Related]
25. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
Williams JP; Kim I; Ito E; Shi W; Yue S; Siu LL; Waldron J; O'Sullivan B; Yip KW; Liu FF
PLoS One; 2014; 9(5):e98557. PubMed ID: 24853121
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
27. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel Impedes EGFR-mutated PC9 Cell Growth
Mohiuddin M; Kasahara K
Cancer Genomics Proteomics; 2021; 18(5):645-659. PubMed ID: 34479917
[TBL] [Abstract][Full Text] [Related]
29. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
Suh YA; Jo SY; Lee HY; Lee C
Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
[TBL] [Abstract][Full Text] [Related]
31. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
[TBL] [Abstract][Full Text] [Related]
32. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
33. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
34. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
[TBL] [Abstract][Full Text] [Related]
35. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
Zhu Y; Shah K
Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
[TBL] [Abstract][Full Text] [Related]
36. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
37. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
38. Scutebarbatine A induces ROS-mediated DNA damage and apoptosis in breast cancer cells by modulating MAPK and EGFR/Akt signaling pathway.
Hao XS; Feng PP; Zhang YY; Wang FZ; Wang GL; Fei HR
Chem Biol Interact; 2023 Jun; 378():110487. PubMed ID: 37072049
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
40. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells.
Wang AC; Su QB; Wu FX; Zhang XL; Liu PS
Eur J Clin Invest; 2009 Feb; 39(2):157-64. PubMed ID: 19200169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
